FLT3 and acute myeloid leukemia: While in approximately 50% of patients with r/r MCL ± AHN, a partial response was achieved on midostaurin (n = 1), DLI (n = 1) or avapritinib (n = 3), future strategies might focus on maintenance therapy or measurable residual disease-based pre-emptive approaches using effective TKIs, e.g. similar to strategies used in AML patients with FLT3 mutation [45].